Related Experiment Video
Updated: Oct 2, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Low-dose etoposide in the treatment of chronic myelomonocytic leukemia]
K Sato1, T Ushijima, Y Ohbayashi
1Department of Hematology and Oncology, Kanto-Teishin Hospital.
Abstract:
Two cases of chronic myelomonocytic leukemia (CMML) which were successfully treated with low dose etoposide are reported. One case was treated with oral etoposide in daily dose of 25 mg for 3d a week, another case in dose of 50 mg/day. Their white blood cell counts became normal and monocytes decreased after the treatment with etoposide. In the second case, blasts in peripheral blood disappeared and thrombocytopenia was improved. The experience of these cases suggests that low dose etoposide is an useful treatment for CMML.

